Shareholder rights advocates at levi & korsinsky investigate regeneron pharmaceuticals, inc. (regn) regarding possible securities fraud violations

New york, ny / accesswire / november 29, 2024 / levi & korsinsky notifies investors that it has commenced an investigation of regeneron pharmaceuticals, inc. ("regeneron pharmaceuticals, inc.") (nasdaq:regn) concerning possible violations of federal securities laws. on october 31, 2024, regeneron released its third quarter 2024 financial results, reporting "u.s. net sales for eylea hd® and eylea® increased 3% versus third quarter 2023 to $1.54 billion, including $392 million from eylea hd.
REGN Ratings Summary
REGN Quant Ranking